Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in Pediatric Patients With Relapsed or Refractory RAS-Driven Tumors
NCT07819838Phase 2Not yet recruiting
- Sponsor
- Children's Oncology Group
- Start
- Apr 2027
- Primary completion
- Apr 2032
01
Overview
Phase 2, open-label, single-arm trial of daraxonrasib in solid tumor, neuroblastoma and rhabdomyosarcoma (RMS), sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose, Incidence of Adverse Events up to 5 years and 1 more. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
daraxonrasib
03
Conditions
solid tumorneuroblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT07819838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819838.